. Because a study may consist of multiple probes, HCFA has priced 83912 at one-fifth the former price and will allow for multiple billings of 83912 up to the total number of probes performed.
Summary
Payers recognize that new technologies may bring large benefits for some patients; however, because common medical procedures are often not subject to hard scientific validation, it is difficult for the payers to determine in which cases the procedures will produce the expected benefits (12). It is up to us to document which tests contribute to the quality of care and are in the best interest of the patient. We must communicate this to payers and work with the local carrier Medical Director in obtaining payment for new technologies.
Equal access to a technology is not possible until the technology is fully reimbursed.
In addition, we must keep informed and become part of the process as we move toward a capitated system.
The question then will be, Can we continue to afford to perform these procedures if they are included under a negotiated capitated plan? It remains to be seen whether firms that develop and bring to market these new technologies will be able to survive in a market where the cost of providing services is fixed regardless of the actual cost.
